Surgical Science Sweden AB (0AAU)
London Stock Exchange · UK · prices in SEK · close of 27 Oct 2026
Key indicators
| Last close | SEK 59.25 |
|---|---|
| 52-week range | 24.02 – 88.40 |
| Return, 1 month / 3 months | – / +92.1% |
| Return, 1 year / 3 years | −33.0% / −50.8% |
| Trend | Uptrend |
| RSI (14) | 88 |
| Volatility (1 year) | 113.5% |
| Worst drawdown (1 year) | -74.9% |
| Average daily value traded | 0.03M SEK |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Surgical Science Sweden AB develops virtual reality simulators and software for training surgeons and medical professionals. Its simulator platforms let clinicians practise minimally invasive procedures such as laparoscopy and endoscopy in a realistic digital environment, with performance feedback built into the exercises. Customers include hospitals, medical schools and training centres that use the systems for skills development and assessment. The company is based in Gothenburg, Sweden, and provides its products and related services to healthcare and educational markets internationally.
Surgical Science Sweden AB trades under the code 0AAU on the London Stock Exchange in UK, with its price quoted in Swedish kronor (SEK). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Surgical Science Sweden AB (0AAU) trades on the London Stock Exchange in UK. It last closed at SEK 59.25 on 27 October 2026.
Its price-based Market X-Ray is 37 out of 100 (a weak price profile), ranking 2,784 of 3,788 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 33.0% and over the last three months it rose 92.1%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 51 · Fair | Mixed trend against its averages. | |
| Above 200-day average | 58.1% | ||
| From 52-week high | -33.0% | ||
| Momentum | 68 · Fair | Typical recent returns for this exchange. | |
| 3-month return | 92.1% | ||
| 6-month return | 69.1% | ||
| 12-month return, skipping the last month | -40.2% | ||
| Stability (higher is calmer) | 5 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 113.5% | ||
| Worst drawdown, 1 year (smaller is calmer) | -74.9% | ||
| Liquidity | 15 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.03M SEK | ||
| Zero-volume days | 35.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | – |
|---|---|
| 1 month | – |
| 3 months | +92.1% |
| 6 months | +69.1% |
| 1 year | −33.0% |
| 3 years | −50.8% |
| 5 years | – |
Signals
| 50-day / 200-day average | 35.25 / 37.47 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 1.89 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.